UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): July 31, 2019
NABRIVA THERAPEUTICS PLC
(Exact name of registrant as specified in its charter)
Ireland |
|
001-37558 |
|
Not Applicable |
(State or other jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer Identification |
25-28 North Wall Quay, |
|
Not Applicable |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (610) 816-6640
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which |
Ordinary Shares, nominal value $0.01 per share |
|
NBRV |
|
The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the Annual General Meeting of Shareholders of Nabriva Therapeutics plc (the Company) held on July 31, 2019, the Companys shareholders voted on the following proposals:
(1) The Companys shareholders elected the following nominees to serve as directors until the 2020 Annual General Meeting of Shareholders.
Name |
|
For |
|
Against |
|
Abstain |
|
Broker |
|
Daniel Burgess |
|
33,676,568 |
|
114,381 |
|
123,320 |
|
22,090,266 |
|
Theodore Schroeder |
|
33,739,046 |
|
111,944 |
|
63,279 |
|
22,090,266 |
|
Colin Broom, M.D. |
|
33,694,565 |
|
91,384 |
|
128,320 |
|
22,090,266 |
|
Carrie Bourdow |
|
33,641,071 |
|
143,578 |
|
129,620 |
|
22,090,266 |
|
Mark Corrigan, M.D. |
|
33,673,043 |
|
118,906 |
|
122,320 |
|
22,090,266 |
|
Charles A. Rowland, Jr. |
|
33,669,160 |
|
116,789 |
|
128,320 |
|
22,090,266 |
|
George H. Talbot, M.D. |
|
33,562,181 |
|
229,168 |
|
122,920 |
|
22,090,266 |
|
Stephen Webster |
|
33,670,278 |
|
111,817 |
|
132,174 |
|
22,090,266 |
|
(2) The Companys shareholders ratified the selection of KPMG LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2019 and authorized, in a binding vote, the Companys board of directors, acting through the audit committee, to set the independent registered public accounting firms remuneration.
For |
|
Against |
|
Abstain |
|
54,990,376 |
|
635,724 |
|
378,435 |
|